An international team of researchers, led by Dr Ozren Bogdanovic and Professor Ryan Lister from the University of Western Australia, have found the genetic “switch” that causes one species of animal to look similar to another.
Mice, fish, frogs and even humans look remarkably similar at early embryonic stages, and appear to share the same molecular instructions that are crucial to normal embryo development.
The study, published in Nature Genetics answers one of the fundamental questions in what controls embryo formation. It also provides insights into the mechanisms that could be linked to developmental disorders or cancers.
Signposts that determine the fate of cells
There is a point during early embryonic development, called the “phylotypic stage”, when all animals with backbone, also known as vertebrates, resemble one another. At this stage, a chicken embryo looks almost indistinguishable from a rabbit or a human at a similar stage.
The time it takes to reach the phylotypic stage varies between species. In humans it takes around four weeks after fertilisation, compared to one to two days in fish and toads, to nearly ten days in mice.
However the process that determines how the embryo reaches this stage was unknown.
The phylotypic stage is crucial as it is the period where the template of the body is being laid down. What genes contribute to this crucial period, and how they are turned on in sync, has been a big question.
The researchers found that specific biochemical signals, known as epigenetic changes, decided the fate of the cells in the early embryo. One particular epigenetic mechanism was DNA methylation, which is able to modify DNA molecules and effectively switch off certain genes during embryo development.
The removal of this epigenetic mark would trigger activity of a whole battery of genes that accomplish these first, highly conserved, developmental stages.
“Our findings answer one of the questions about early development, such as the molecular mechanisms that make a ‘heart’ a ‘heart’ and or a ‘limb’ a ‘limb’”, said Dr Ozren Bogdanovic, lead author from the ARC Centre of Excellence in Plant Energy Biology.
In addition, one protein, TET, which in mammals is activated right after fertilisation, was detected the protein in fish and frogs as well during the phylotypic stage.
This means species that were distantly related on the evolutionary scale, even after millions of years, all had the same molecular basis that defined the blueprint of body formation.
A longstanding puzzle solved
Jenny Graves, professor of genetics at La Trobe University, who was not involved in the study, is also one of the first researchers to demonstrate DNA methylation. She said that these findings had significant implications across the field of molecular genetics.
“It’s very significant indeed. It’s a huge paper with an enormous amount of work,” she said. “I’ve always thought that DNA methylation probably had a big role in development, so I’m jumping for joy.”
The study has helped solve a longstanding puzzle on early embryo development.
“There were all kinds of theories going way way back,” she said, stressing the growing impact of epigenetics, the study of the epigenome.
“Every change during development is probably modulated by the epigenome that determines the basic embryonic patterning of vertebrates, and probably also turns on later genes that specify differences between a frog, or a fish or mouse.”
Graves said a next step will be searching for even more conserved patterns across all species. “Some of the most fundamental controls of the way genes work would probably be the same in a plant, or a fruit fly or a mouse.”
It is also certain that humans share the same pathway in embryo development as other species. This common pattern would mean that prior to birth, there is a point where we are virtually indistinguishable in appearance to other species.
“It would be really extraordinary if it weren’t,” said Graves. “It is probably going to turn out that all mammals share these very fundamental patterns and it would be amazing if humans were any different.”
This article was originally published on The Conversation. Read the original article.



Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 



